论文部分内容阅读
目的 研究99m 锝标记肝癌单克隆抗体HAb18及其片段F(ab′) 2 在正常小鼠体内的药代动力学。方法 4组小鼠经尾静脉分别注入 7.5MBq99mTc HAb18;0 .9MBq ,7.5MBq ,37MBq99mTc F(ab′) 2 ,在不同时间点测尾血的放射性计数。另取 18只小鼠尾静脉注入 7.5MBq99mTc F(ab′) 2 在不同点处死 ,测量各脏器放射性计数。结果 99mTc F(ab′) 2 ,99mTc HAb18的药代动力学均符合二室开放模型 ,二者在 7.5MBq剂量时有关的参数分别为t1 2 β(5 .3± 0 .4)h ,(15 .5± 1.4)h (P <0 .0 5 ) ;Vc(12 9.2± 2 3.7)μl·g- 1 ,(10 3 .5± 6 .8) μl·g- 1 (P >0 .0 5 ) ;CL(6 3.4± 12 .5 ) ,(10 .6± 1.3) μl·g·h- 1 (P <0 .0 1) ;AUC(0 .0 0 7± 0 .0 0 1) ,(0 .0 4± 0 .0 0 7)MBq·h·μl- 1 (P <0 .0 1)。结论 不同剂量的99mTc F(ab′) 2 消除属一级消除动力学
Objective To study the pharmacokinetics of the 99m-labelled liver cancer monoclonal antibody HAb18 and its fragment F(ab’) 2 in normal mice. Methods Four groups of mice were injected with 7.5MBq99mTc HAb18, 0.9Mbq, 7.5MBq, and 37MBq99mTc F(ab’)2 via tail vein respectively. The radioactivity counts were measured at different time points. Another 18 mice were injected into the tail vein to inject 7.5MBq99mTc F(ab’) 2 at different points. The radioactivity count of each organ was measured. Results The pharmacokinetics of 99mTc F(ab’) 2 ,99mTc HAb18 were all consistent with the two-compartment open model. The relevant parameters were tl2β(5.3±0.4)h at the dose of 7.5MBq,( 15. 5 ± 1.4)h (P <0.05); Vc (12 9.2 ± 2 3.7) μl·g-1, (10 3 ·5 ± 6.8) μl·g - 1 (P > 0. 0 5 ) ; CL (6 3.4 ± 12 .5), (10 .6 ± 1.3) μl·g·h - 1 (P <0.01); AUC (0.07 ± 0. 0 0 1 ), (0. 0 4 ± 0. 0 0 7) MBq · h · μl - 1 (P <0. 0 1). Conclusion Different dosages of 99mTc F(ab’) 2 eliminate the first-order elimination kinetics